Genomics Immune Response In-Vitro 
The Pharma Data
JANUARY 11, 2021
Dalcetrapib is a potential anti-viral treatment that binds to the catalytic site of 3CLMpro of SARS-CoV-2 in vitro. Centers for Disease Control and Prevention (CDC) to provide genomic sequencing of SARS-CoV-2 samples. News information is not all-inclusive and updates are published once a week on Tuesdays. . . Diagnostics.
Cloudbyz
JULY 31, 2024
In precision medicine, biomarkers are used to identify patients who will benefit from specific therapies, predict disease progression, and monitor treatment responses. Monitoring Treatment Response: Regular diagnostic testing can monitor the effectiveness of treatments by measuring changes in biomarker levels.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 16, 2021
1 lineage gained prominence in late 2020, with each carrying a number of genomic mutations. 1.351 carries another spike mutation E484K, which appears to evade the body’s immune response, possibly diminishing vaccine efficacy. 1.1.7), South Africa (B.1.351), 1.351), and Brazil (P.1). Variants of B.1.1.7, 1.351 and P.1
The Pharma Data
MAY 4, 2021
Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study. Tecentriq approval offers an alternative to chemotherapy for all eligible patients. We are delighted to bring Tecentriq to people in the EU with this specific type of lung cancer,” said Levi Garraway, M.D.,
XTalks
NOVEMBER 20, 2020
The cell-based tests are designed to identify specific T cells that are activated in response to a pathogen — which in this case would be SARS-CoV-2. Traditional antibody tests for uncovering past infections involve detection of antigen-specific antibodies produced during an immune response against a pathogen.
Expert insights. Personalized for you.
52 
Let's personalize your content